VEO Ophthalmics to Support The Masket Foundation to Raise Awareness of Aniridia

VEO Ophthalmics announced that, in honor of Rare Disease Day, it is collaborating with the Masket Foundation to raise awareness of aniridia and treatment options for aniridia. Aniridia is a serious ophthalmic rare disease in which a patient’s iris does not develop properly. VEO Ophthalmics is the U.S. distributor for the Customflex ArtificialIris, a custom-made artificial iris implant that addresses both symptomatic and cosmetic aspects of iris defects. VEO Ophthalmics and the Masket Foundation are working together to expand patient access.

Rare Disease Day, which takes place on the last day of February each year, was created to raise global awareness about rare diseases and their impact on patients’ lives. The campaign targets the general public, as well as policy makers, public authorities, industry representatives, researchers, and health professionals.

“Symptomatic aniridia is a serious condition with far-reaching lifestyle implications. Following the FDA approval of the Customflex ArtificialIris, many patients have benefited from this unique technology,” Ron Gilliland, President and CEO of VEO Ophthalmics, said in a company news release. “To raise awareness of this disease among the general public, we are honored to support the Masket Foundation, whose crucial work in ophthalmic research stands to help many patients suffering from aniridia and other ophthalmic diseases.”

“The work we do at the Masket Foundation is largely driven by our strategic partnerships with industry, and our partnership with VEO Ophthalmics is a shining example of that,” Samuel Masket, MD, Founder of the Masket Foundation, said in the news release. “A core part of our mission is to raise awareness of many rare or orphan-status ophthalmic diseases, including symptomatic aniridia. We are grateful for VEO Ophthalmics’ support and look forward to continuing our work during Rare Disease Day – and beyond.”